Prevalence of Factor V Genetic Variants Associated With Indian APCR Contributing to Thrombotic Risk

Detection of Exon 10 Mutation (rs6020) in Factor V Gene in Sudanese patients with Deep Vein Thrombosis.. [DOI: 10.21203/rs.3.rs-2500709/v1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0]

Background: Deep vein thrombosis (DVT), a subgroup of venous thromboembolism (VTE), is one of the leading causes of morbidity and mortality globally, accounting for 60,000-100,000 fatalities per year. It affects around 0.1 percent of the population each year. In Sudanese patients with DVT, this study looked for probable harmful single nucleotide polymorphisms in exon 10 of the factor V gene. Method: Thirty blood samples were obtained from previously diagnosed DVT patients at Omdurman teaching hospital throughout the period of 16 August to 25 October 2018, as part of a descriptive cross-sectional research in Khartoum state. Exon 10 was amplified by PCR using sequence-specific primers after DNA was extracted using the guanidine chloride procedure. The fifteen best bands' PCR products were sequenced in both directions (BGI Company). Bioinformatics techniques were used to examine the sequences (Finch TV, BLAST, and Codon Code alignment). Result: The presence of a missense mutation (rs6020) in the factor V Leiden gene was discovered in 40% (6/15) of the patients in this investigation. In five cases, this mutation was heterozygous, whereas in one patient, it was homozygous. In the other nine cases, no mutations were found. Conclusion: rs6020 is more prevalent in the Sudanese population than other types of mutations. rs6020 polymorphism has a strong association with deep vein thrombosis in the Sudanese population. Further investigation of this mutation amongst larger Sudanese population is required in order to support this finding as well as to understand its clinical significance.

Hemostasis and Thrombosis: An Overview Focusing on Associated Laboratory Testing to Diagnose and Help Manage Related Disorders

Hemostasis is a complex but balanced process that permit normal blood flow, without adverse events. Disruption of the balance may lead to bleeding or thrombotic events, and clinical interventions may be required. Hemostasis laboratories typically offer an array of tests, including routine coagulation and specialized hemostasis assays used to guide clinicians for diagnosing and managing patients. Routine assays may be used to screen patients for hemostasis-related disturbances but may also be used for drug monitoring, measuring efficacy of replacement or adjunctive therapy, and other indications, which may then be used to guide further patient management. Similarly, "specialized" assays are used for diagnostic purposes or may be used to monitor or measure efficacy of a given therapy. This chapter provides an overview of hemostasis and thrombosis, with a focus on laboratory testing that may be used to diagnose and help manage patients suspected of hemostasis- and thrombosis-related disorders.

The relationship between gene polymorphism of MTRR A66G and lower extremity deep venous thrombosis

OBJECTIVE

To investigate the relationship between gene polymorphism of MTRR A66G and lower extremity deep venous thrombosis (DVT).

METHODS

Two hundred and two patients with DVT as experimental group and 240 normal adults (control group) were enrolled in this study and white blood cells were collected, respectively. Polymorphism of the 66 loci in MTRR gene was detected by polymerase chain reaction-sequence-specific primers (PCR-SSP) in two groups. The frequency of genotype and allele distribution of each group was compared.

RESULTS

The frequency of AA, AG and GG genotypes in 66 sites of MTRR gene were 26.76%, 4 3.66% and 29.58% in DVT group and 43.57%, 44.28% and 12.14% in control group, respectively. There was no significant difference in the distribution frequency between two groups (χ = 3.2, P > .5).

CONCLUSIONS

The gene polymorphism of MTRR A66G may not be an independent genetic risk factor in DVT in China.